Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.
Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up